SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition

Upregulation of the PI3K pathway has been implicated in the initiation and progression of several types of cancer, including renal cell carcinoma (RCC). Although several targeted therapies have been developed for RCC, durable and complete responses are exceptional. Thus, advanced RCC remains a letha...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Terzo, Esteban A., Lim, Aaron R., Chytil, Anna, Chiang, Yun Chen, Farmer, Leah, Gessner, Kathryn H., Walker, Cheryl Lyn, Jansen, Valerie M., Rathmell, W. Kimryn
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2019
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363018/
https://ncbi.nlm.nih.gov/pubmed/30774762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26567
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg